Navigation Links
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
Date:10/29/2009

loan from Bay City Capital;
  • our ability to timely recruit and enroll patients in any future clinical trials;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;
  • the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;
  • our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;
  • our ability to successfully commercialize VIA-2291;
  • our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;
  • our ability to obtain and protect our intellectual property related to our product candidates;
  • our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
  • our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item 1A "Risk
    '/>"/>

  • SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine news :

    1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
    2. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
    3. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
    4. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
    5. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
    6. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
    7. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
    8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
    9. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
    10. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
    11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
    (Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
    (Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
    (Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
    (Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
    Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
    ... TUESDAY, Aug. 30 (HealthDay News) -- Genes affect hereditary coronary ... a new study. While it,s long been known that ... this is due to genes or unhealthy lifestyle in the ... that question, the investigators examined the health records of 80,214 ...
    ... not how old but how frail patients are that can predict ... young patients in poor health may have worse outcomes than older ... University of Michigan Comprehensive Cancer Center finds that patients with decreased ... to distant parts of the body. These findings may ...
    ... of Medicine researchers have found that climate change may lead ... room (ER) visits in the next decade. The data, ... Preventive Medicine, found that changing levels of ozone could lead ... by children, ages 0-17. The research team, ...
    ... August 30, 2011Despite recent concerns that changes in atmospheric ... insulin delivered via pump devices, the current evidence is ... more data are available, according to an insightful editorial ... journal published by Mary Ann Liebert, Inc. The editorial ...
    ... An Indiana University study that compared strategies used by extroverted ... happy people who are less outgoing relied less on partying ... family and friends or cognitive strategies, such as positive thinking. ... to be happy. That,s the thing students feel they need ...
    ... TUESDAY, Aug. 30 (HealthDay News) -- Swedish scientists have identified ... a harbinger of an increased risk of death among elderly ... the inflammatory processes that are central to killers such as ... study, published online Aug. 30 in the Journal of ...
    Cached Medicine News:Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News: Happiness: All in who you know, goals 2Health News:Blood Protein Might Signal Death Risk in Elderly 2
    (Date:9/15/2014)... 2014 The Society of Corporate Compliance ... more than 4,500 compliance and ethics professionals from ... chronicles corporate fines and settlements.  The SCALENDAR is ... a ready reference to demonstrate to employees the ... SCALENDAR to help compliance and ethics officers looking ...
    (Date:9/15/2014)... Sept. 15, 2014  Over 200 patients, families, ... Saturday to learn, interact and participate in the ... first Lupus Trials Fair launched by the ... S.L.E. Lupus Foundation .  Attendees interacted directly with ... sharing experiences, ideas and needs and learning about ...
    (Date:9/15/2014)... , Sept. 15, 2014 Research ... "Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014" ... (CAS 103-90-2) Market Research Report 2014 presents comprehensive data ... Europe , Asia , ... The report includes paracetamol (acetaminophen) description, covers its application ...
    Breaking Medicine Technology:More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3
    ... Since the 1950s, the American,Heart Association (AHA) ... take,antibiotics before having dental work or other procedures ... were supposed to prevent,infective endocarditis, a potentially serious ... the latest evidence, the AHA now emphasizes routine,oral ...
    ... Board Recommends Continuing Study, NEW YORK, Oct. ... announced today the completion of interim analysis of ... drug candidate,pafuramidine. An independent Data Safety Monitoring Board ... trial should continue as,planned. The trial is evaluating ...
    Cached Medicine Technology:For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter 2Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial 2Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial 3Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial 4
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: